Ferring Position on Alabama Supreme Court Ruling in LePage v Mobile Infirmary Clinic
Parsippany, NJ – February 27, 2024 – Ferring stands with the American Society for Reproductive Medicine, RESOLVE: The National Infertility Association and others and strongly opposes any action that restricts or impairs a person’s ability to fully access in vitro fertilization (IVF) – a well-established medical procedure, which helps couples and individuals realize their dreams of becoming parents.
Ferring believes that the Alabama Supreme Court’s ruling in LePage v Mobile Infirmary Clinic has already led to unintended adverse repercussions on patients’ access to infertility treatments, including IVF.
Ferring believes that healthcare decisions should be the purview of patients and their physicians. We are committed to advancing fertility care to help more people achieve their dreams of parenthood.
###
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately-owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. In the United States, Ferring is a leader in reproductive medicine and maternal health, and in areas of gastroenterology and orthopaedics. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Our company was founded in 1950 and is headquartered in Saint-Prex, Switzerland. Ferring employs more than 7,000 people worldwide and markets its medicines in over 100 countries. Ferring USA is based in Parsippany, New Jersey, and employs more than 900 employees.
For more information, please visit www.ferringusa.com, call 1-888-FERRING (1-888-337-7464), or connect with us on LinkedIn, and X (Twitter).
US Communications
Tel. (862) 286-5035
Email: US.Communications@Ferring.com